Validity of a Newly Synthesized Instrument to Measure Fatigue and Depression in Hepatitis C Patients

2.50
Hdl Handle:
http://hdl.handle.net/10755/155737
Type:
Presentation
Title:
Validity of a Newly Synthesized Instrument to Measure Fatigue and Depression in Hepatitis C Patients
Abstract:
Validity of a Newly Synthesized Instrument to Measure Fatigue and Depression in Hepatitis C Patients
Conference Sponsor:Sigma Theta Tau International
Conference Year:2001
Conference Date:June, 2001
Author:Eriksen, Lillian, DNS/DNSc/DSN
P.I. Institution Name:University of Texas Health Science Center at Houston
Title:Associate Professor
Objective: To test the validity of a newly synthesized instrument to measure fatigue and depression in hepatitis C patients. Design: This psychometric study used a hypothesis testing approach to examine the validity of the synthesized instrument for use with hepatitis C patients. The new instrument is composed of items from two other instruments, one measuring fatigue (Piper Fatigue Scale, PFS) and the other measuring depression (The Center for Epidemiologic Studies Depression Scale CES-D). The construction of the synthesized instrument was the result of a previous study. The hypothesis projected statistically significant differences in the levels of fatigue and depression in hepatitis C patients after receiving pharmacological treatment for hepatitis C. Population, Sample, Setting, Years: The population consisted of 298 chronic hepatitis C patients with hepatitis C and no other current physiologic illness. The sample will consist of approximately 100 of these patients who had completed four weeks of treatment with a combination of recombinant interferon alfa-2b and ribavirin. The study is being conducted at three different university affiliated outpatient hepatitis C clinics. Participants were recruited from March 1999 and will continue through January2001. Concept or Variables Studied Together or Intervention and Outcome Variables: Fatigue is the most common symptom reported by chronic hepatitis C patients. After beginning pharmacological treatment fatigue increases. This increase in fatigue has lead to dose reduction and discontinuation of treatment, both of which may interfere with the efficacy of the pharmacological treatment. Depression further confounds the situation as it is both a side effect of the treatment and is also associated with fatigue. Methods: The synthesized instrument was administered to willing participants, in a private room in the clinic. A repeated measures analysis of variance will be used to assess difference in scores between the two testings (1-prior to treatment and 2- 4 weeks after treatment). Findings: As hypothesized, the repeated measures ANOVA revealed a statistically significant increase in the symptoms of fatigue and depression following pharmacological treatment. Conclusions: The newly synthesized instrument is a valid measure of changes in symptomatology. Implications: Thus it is important to be able to identify and monitor the levels of both these variables so that they can be treated. Control of fatigue and depression are essential to assure the chance for the most efficacious outcome for the patients.
Repository Posting Date:
26-Oct-2011
Date of Publication:
Jun-2001
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleValidity of a Newly Synthesized Instrument to Measure Fatigue and Depression in Hepatitis C Patientsen_GB
dc.identifier.urihttp://hdl.handle.net/10755/155737-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Validity of a Newly Synthesized Instrument to Measure Fatigue and Depression in Hepatitis C Patients</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2001</td></tr><tr class="item-conference-date"><td class="label">Conference Date:</td><td class="value">June, 2001</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Eriksen, Lillian, DNS/DNSc/DSN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of Texas Health Science Center at Houston</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Associate Professor</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">lillian.eriksen@uth.tmc.edu</td></tr><tr><td colspan="2" class="item-abstract">Objective: To test the validity of a newly synthesized instrument to measure fatigue and depression in hepatitis C patients. Design: This psychometric study used a hypothesis testing approach to examine the validity of the synthesized instrument for use with hepatitis C patients. The new instrument is composed of items from two other instruments, one measuring fatigue (Piper Fatigue Scale, PFS) and the other measuring depression (The Center for Epidemiologic Studies Depression Scale CES-D). The construction of the synthesized instrument was the result of a previous study. The hypothesis projected statistically significant differences in the levels of fatigue and depression in hepatitis C patients after receiving pharmacological treatment for hepatitis C. Population, Sample, Setting, Years: The population consisted of 298 chronic hepatitis C patients with hepatitis C and no other current physiologic illness. The sample will consist of approximately 100 of these patients who had completed four weeks of treatment with a combination of recombinant interferon alfa-2b and ribavirin. The study is being conducted at three different university affiliated outpatient hepatitis C clinics. Participants were recruited from March 1999 and will continue through January2001. Concept or Variables Studied Together or Intervention and Outcome Variables: Fatigue is the most common symptom reported by chronic hepatitis C patients. After beginning pharmacological treatment fatigue increases. This increase in fatigue has lead to dose reduction and discontinuation of treatment, both of which may interfere with the efficacy of the pharmacological treatment. Depression further confounds the situation as it is both a side effect of the treatment and is also associated with fatigue. Methods: The synthesized instrument was administered to willing participants, in a private room in the clinic. A repeated measures analysis of variance will be used to assess difference in scores between the two testings (1-prior to treatment and 2- 4 weeks after treatment). Findings: As hypothesized, the repeated measures ANOVA revealed a statistically significant increase in the symptoms of fatigue and depression following pharmacological treatment. Conclusions: The newly synthesized instrument is a valid measure of changes in symptomatology. Implications: Thus it is important to be able to identify and monitor the levels of both these variables so that they can be treated. Control of fatigue and depression are essential to assure the chance for the most efficacious outcome for the patients.</td></tr></table>en_GB
dc.date.available2011-10-26T14:07:38Z-
dc.date.issued2001-06en_GB
dc.date.accessioned2011-10-26T14:07:38Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.